News and publications

Invoke Bio's NEMo: Evolutionary Machine Learning for Neoantigen Immunogenicity Prediction

NEMo uses evolutionary machine learning trained on 25,000+ immune checkpoint blockade mutations, treating immune-driven neoantigen elimination as a training signal. Validated across the TESLA benchmark and two cancer vaccine clinical trials.

More news

Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data
Open Data
News
October 2026
Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data
Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI
QB3
News
October 2026
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI
Learning What Cancer Reveals: Introducing NEMo
bioRxiv Preprint
Publication
September 2026
Learning What Cancer Reveals: Introducing NEMo
Learning What Cancer Reveals: Introducing NEMo
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
QB3
News
June 2026
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
See all
news